Single Heterocyclic Compounds as Monoamine Oxidase Inhibitors: From Past to Present

Su-Min Wu; Xiao-Yang Qiu; Shu-Juan Liu; Juan Sun

doi:10.2174/1389557520666200302114620

Single Heterocyclic Compounds as Monoamine Oxidase Inhibitors: From Past to Present

Mini Rev Med Chem. 2020;20(10):908-920. doi: 10.2174/1389557520666200302114620.

Authors

Su-Min Wu¹, Xiao-Yang Qiu^{1

2}, Shu-Juan Liu¹, Juan Sun³

Affiliations

¹ College of Science & Technology, Ningbo University, Ningbo, 315212, China.
² State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian 350002, China.
³ School of Biological & Chemical Engineering, Zhejiang University of Science & Technology, Hangzhou 310023, China.

PMID: 32116191
DOI: 10.2174/1389557520666200302114620

Abstract

Inhibitors of monoamine oxidase (MAO) have shown therapeutic values in a variety of neurodegenerative diseases such as depression, Parkinson's disease and Alzheimer's disease. Heterocyclic compounds exhibit a broad spectrum of biological activities and vital leading compounds for the development of chemical drugs. Herein, we focus on the synthesis and screening of novel single heterocyclic derivatives with MAO inhibitory activities during the past decade. This review covers recent pharmacological advancements of single heterocyclic moiety along with structure- activity relationship to provide better correlation among different structures and their receptor interactions.

Keywords: FAD; H2O2; Monoamine oxidase inhibitors; bioactivities; heterocyclic compounds; structure-activity relationship..

Publication types

Review

MeSH terms

Drug Discovery*
Heterocyclic Compounds / chemistry
Heterocyclic Compounds / pharmacology*
Humans
Monoamine Oxidase Inhibitors / chemistry
Monoamine Oxidase Inhibitors / pharmacology*

Substances

Heterocyclic Compounds
Monoamine Oxidase Inhibitors